Alumis公司宣布,其候选药物Envudeucitinib在临床研究中展现出良好的安全性和耐受性特征,这一结果与二期临床试验项目的数据保持一致。
Alumis公司宣布,其候选药物Envudeucitinib在临床研究中展现出良好的安全性和耐受性特征,这一结果与二期临床试验项目的数据保持一致。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.